Cellerant Therapeutics
Filgrastim(Cellerant Therapeutics)은 Hodgkin Lymphoma 표적 ADC로, Male Breast Cancer; Stage II Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitmen. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT00057811). PK: t½ 3.5 h.
Hodgkin Lymphoma
Male Breast Cancer; Stage II Breast Cancer
Recruiting
Vedotin Therapy]
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitmen…
downregulation of major histocompatibility complex II (HLA-DR) and the ability to suppress T-cell proliferation in vitro
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Cellerant Therapeutics
Filgrastim(Cellerant Therapeutics)은 Hodgkin Lymphoma 표적 ADC로, Male Breast Cancer; Stage II Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitmen. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT00057811). PK: t½ 3.5 h.
Hodgkin Lymphoma
Male Breast Cancer; Stage II Breast Cancer
Recruiting
Vedotin Therapy]
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitmen…
downregulation of major histocompatibility complex II (HLA-DR) and the ability to suppress T-cell proliferation in vitro
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.